# Study Guide: 2020 American College of Rheumatology Guideline for the Management of Gout This study guide is designed to synthesize the clinical recommendations and evidence-based strategies outlined in the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout. It focuses on the indications for urate-lowering therapy (ULT), titration strategies, flare management, and lifestyle recommendations. --- ## Key Concepts and Clinical Recommendations ### 1. Indications for Urate-Lowering Therapy (ULT) The guidelines categorize the initiation of ULT into strong and conditional recommendations based on disease severity and frequency of symptoms. | Recommendation Strength | Indications for Initiating ULT | | :--- | :--- | | **Strongly Recommended** | Presence of $\ge1$ subcutaneous tophi; evidence of radiographic damage attributable to gout; or frequent gout flares ($\ge2$ annually). | | **Conditionally Recommended** | Patients with $>1$ flare but infrequent ($<2$ annually); first flare with comorbid moderate-to-severe CKD (stage $\ge3$); $SU >9$ mg/dl; or urolithiasis. | | **Conditionally Against** | Patients experiencing their first gout flare with no comorbidities; or patients with asymptomatic hyperuricemia ($SU >6.8$ mg/dl with no prior flares or tophi). | ### 2. ULT Selection and Dosing Strategies The guideline emphasizes a "start low and go slow" approach to minimize the risk of Allopurinol Hypersensitivity Syndrome (AHS) and treatment-induced flares. * **First-Line Agent:** Allopurinol is strongly recommended as the preferred first-line agent for all patients, including those with Chronic Kidney Disease (CKD) stage $\ge3$. * **Initial Dosing:** * **Allopurinol:** $\le100$ mg/day (lower in patients with CKD). * **Febuxostat:** $<40$ mg/day. * **Probenecid:** 500 mg once or twice daily (titrate subsequently). * **Genetic Testing:** Testing for the $HLA-B*5801$ allele is conditionally recommended before starting allopurinol for patients of Southeast Asian descent (Han Chinese, Korean, Thai) and African American patients due to a higher prevalence of the allele and associated risk of AHS. * **Prophylaxis:** When initiating ULT, concomitant anti-inflammatory prophylaxis (e.g., colchicine, NSAIDs, or prednisone) is strongly recommended for a duration of **3–6 months**. ### 3. The Treat-to-Target Strategy The guideline strongly advocates for a treat-to-target management strategy over a fixed-dose approach. * **Target Level:** Achievement and maintenance of a serum urate (SU) target of **$<6$ mg/dl**. * **Titration:** Dose titration should be guided by serial SU measurements. * **Delivery of Care:** The use of an augmented protocol (incorporating nurse or pharmacist-led education and titration) is conditionally recommended to improve adherence and outcomes. ### 4. Management of Gout Flares First-line treatment for flares should be initiated early and prioritized based on patient factors. * **Preferred Agents:** Colchicine, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), or Glucocorticoids (oral, intra-articular, or intramuscular). * **Colchicine Dosing:** Low-dose colchicine (1.2 mg followed by 0.6 mg one hour later) is strongly recommended over high-dose colchicine due to similar efficacy and fewer side effects. * **Advanced Options:** IL-1 inhibitors are conditionally recommended for patients who cannot tolerate or have contraindications to conventional first-line therapies. ### 5. Lifestyle and Concurrent Medications Lifestyle changes are recommended as adjuvants to pharmacologic therapy, though they typically yield only modest changes in SU concentration. | Category | Recommendation | | :--- | :--- | | **Dietary Limits** | Conditionally recommend limiting alcohol, purine-rich foods, and high-fructose corn syrup. | | **Weight Management** | Conditionally recommend a weight loss program for overweight or obese patients. | | **Antihypertensives** | Conditionally recommend switching hydrochlorothiazide to an alternative and preferentially choosing losartan when feasible. | | **Aspirin** | Conditionally recommend **against** stopping low-dose aspirin if taken for appropriate medical indications. | | **Vitamin C** | Conditionally recommend **against** adding vitamin C supplementation. | --- ## Short-Answer Practice Questions 1. **What is the specific SU target recommended for patients on ULT?** * *Answer:* A target of $<6$ mg/dl. 2. **Why is it recommended to start allopurinol at a dose of $\le100$ mg/day?** * *Answer:* To mitigate the risk of Allopurinol Hypersensitivity Syndrome (AHS) and to reduce the risk of flares associated with the initiation of therapy. 3. **For which specific populations is $HLA-B*5801$ testing recommended prior to starting allopurinol?** * *Answer:* Patients of Southeast Asian descent (Han Chinese, Korean, Thai) and African American patients. 4. **What is the recommended duration for anti-inflammatory prophylaxis when starting ULT?** * *Answer:* At least 3 to 6 months. 5. **Under what circumstances is pegloticase strongly recommended?** * *Answer:* For patients where XOI, uricosurics, and other interventions have failed to achieve the SU target, and who continue to have frequent gout flares ($\ge2$/year) or non-resolving tophi. 6. **Which common diuretic should be switched to an alternative, if feasible, in gout patients?** * *Answer:* Hydrochlorothiazide. --- ## Essay Questions for Deeper Exploration 1. **Analyze the "Treat-to-Target" approach versus fixed-dose therapy in gout management.** Discuss the clinical evidence supporting the SU target of $<6$ mg/dl and how augmented delivery of care (e.g., nurse-led protocols) enhances patient outcomes. 2. **Evaluate the safety considerations of febuxostat compared to allopurinol.** Detail the findings of the CARES trial regarding cardiovascular (CV) death and explain the ACR's conditional recommendation for switching medications in patients with a history of CVD or new CV events. 3. **Discuss the rationale for the ACR’s recommendations against treating asymptomatic hyperuricemia.** Include the "number needed to treat" to prevent a single incident flare and the potential risks/costs associated with lifelong ULT in patients who may never develop clinical gout. 4. **Explain the role of patient-provider shared decision-making in lifestyle modifications.** Why does the guideline emphasize avoiding "patient-blaming" when discussing diet, and how do genetic factors influence the development of gout relative to dietary choices? --- ## Glossary of Important Terms * **Asymptomatic Hyperuricemia:** A state of elevated serum urate ($\ge6.8$ mg/dl) in a patient who has never experienced a gout flare or subcutaneous tophi. * **Allopurinol Hypersensitivity Syndrome (AHS):** A rare but severe and potentially life-threatening adverse reaction to allopurinol. * **Conditional Recommendation:** A recommendation reflecting scenarios where benefits and risks are closely balanced or supported by low-certainty evidence; these decisions require significant shared decision-making. * **GRADE Methodology:** (Grading of Recommendations Assessment, Development and Evaluation) A systematic process used to rate the certainty of evidence and the strength of medical recommendations. * **$HLA-B*5801$:** A genetic allele that serves as a marker for a high risk of developing severe cutaneous adverse reactions when taking allopurinol. * **PICO Questions:** A framework used to develop guidelines by defining the Population, Intervention, Comparator, and Outcomes. * **Strong Recommendation:** A recommendation where the benefits clearly outweigh the risks, and almost all informed patients and providers would reach the same decision. * **Tophi (Subcutaneous):** Deposits of monosodium urate crystals that form under the skin, often in or near joints, signifying advanced gout. * **Urate-Lowering Therapy (ULT):** Pharmacologic treatments (such as allopurinol, febuxostat, or probenecid) intended to reduce the concentration of uric acid in the blood. * **Xanthine Oxidase Inhibitor (XOI):** A class of medications (including allopurinol and febuxostat) that decreases the production of uric acid.